Universe Pharmaceuticals Inc.
UPC · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | -0.00 |
| FCF Yield | 17,281.52% | -828.67% | -31.27% | -109.11% |
| EV / EBITDA | 13.69 | -4.39 | -0.47 | -0.94 |
| Quality | ||||
| ROIC | -3.70% | -11.90% | -5.51% | -10.81% |
| Gross Margin | 34.57% | 27.88% | 25.18% | 29.36% |
| Cash Conversion Ratio | -0.78 | -1.62 | 0.19 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.71% | -0.18% | 3.88% | 16.09% |
| Free Cash Flow Growth | 133.43% | -195.22% | 32.21% | -176.77% |
| Safety | ||||
| Net Debt / EBITDA | 13.70 | -4.58 | 0.20 | -0.05 |
| Interest Coverage | -18.07 | -44.36 | -12.74 | -44.71 |
| Efficiency | ||||
| Inventory Turnover | 1.43 | 4.21 | 2.57 | 2.92 |
| Cash Conversion Cycle | 84.71 | 119.56 | 63.05 | 58.33 |